Culine S, Theodore C, Farhat F, Bekradda M, Terrier-Lacombe M J, Droz J P
Department of Medicine, Institut Gustave Roussy, Villejuif, France.
J Surg Oncol. 1996 Mar;61(3):195-8. doi: 10.1002/(SICI)1096-9098(199603)61:3<195::AID-JSO6>3.0.CO;2-6.
In order to assess the results of cisplatin-based chemotherapy after primary lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors of the testis, we retrospectively reviewed the long-term outcome of 44 patients who received adjuvant chemotherapy at Institut Gustave Roussy over a 7-year period. Two chemotherapy regimens were sequentially delivered. Twenty-three patients were treated with vinblastine, cyclophosphamide, bleomycin, actinomycin D, and cisplatin (mVAB-6, four cycles), while 21 patients received a combination of etoposide and cisplatin (EP, four cycles). After a median follow-up of 6 years, all patients remain free from progression. The long-term toxicity included retrograde ejaculation in eight patients and severe ototoxicity in two patients. We conclude that four cycles of cisplatin-based chemotherapy for pathological stage II testicular cancer resulted in a 100% cure rate with minimal toxicity.
为了评估睾丸病理II期非精原细胞性生殖细胞肿瘤患者在原发性淋巴结清扫术后基于顺铂的化疗结果，我们回顾性分析了44例在古斯塔夫·鲁西研究所接受了7年辅助化疗患者的长期预后。先后采用了两种化疗方案。23例患者接受了长春碱、环磷酰胺、博来霉素、放线菌素D和顺铂联合治疗（mVAB-6，四个周期），而21例患者接受了依托泊苷和顺铂联合治疗（EP，四个周期）。中位随访6年后，所有患者均无疾病进展。长期毒性包括8例患者逆行射精和2例患者严重耳毒性。我们得出结论，病理II期睾丸癌采用四个周期基于顺铂的化疗可实现100%治愈率，且毒性极小。
